Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)
Malignant Renal Pelvis Neoplasm
Explore 12 assets in Malignant Renal Pelvis Neoplasm →Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Fred Hutchinson Cancer Center
Modality
antibody_drug_conjugate
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05756569CT.gov Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology | — | Recruiting | — | — | — |
NCT04963153CT.gov Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Renal Pelvis Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) (this asset) | Fred Hutchinson Cancer Center | P2 | BB · 65 |
| Pembrolizumab | Fred Hutchinson Cancer Center | P2 | B |
| Atezolizumab | National Cancer Institute (NCI) | P2 | B |
| Apsolol | Emory University | P2 | CCC |
| Eribulin Monomethanesulfonate | National Cancer Institute (NCI) | P2 | CCC |
| Relatlimab | M.D. Anderson Cancer Center | P2 | CCC |
| Nivolumab | M.D. Anderson Cancer Center | P2 | CCC |
| Tocilizumab | M.D. Anderson Cancer Center | P2 | CCC |
| Ipilimumab | M.D. Anderson Cancer Center | P2 | CCC |
+6 more in the Malignant Renal Pelvis Neoplasm cohort
Other indications for Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Urothelial Carcinoma | — | P2/3 | BB · 70 |
| Urinary Bladder Neoplasm | — | P2 | BB · 68 |
| Ureter Neoplasm | — | P2 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) in Malignant Renal Pelvis Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/enfortumab-vedotin-fully-human-monoclonal-antibody-conjugated-to-a-cytotoxic-agent-monomethyl-auristatin-e-mmae-targeting-nectin-4-malignant-renal-pelvis-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →